Concept
Explore research and evidence related to AKT.
1
A case of BRAF V600E wild-type, PD-L1-high anaplastic thyroid cancer that progressed on tyrosine kinase inhibitor therapy achieved a near-complete response lasting over 30 months on pembrolizumab combined with nab-paclitaxel and carboplatin.